The maze of treatments for hepatitis B.
The maze of treatments for hepatitis B.
复制标题
DOI：
10.1056/nejme058119
复制
发表时间：
2005-06
期刊：
影响因子：
--
通讯作者：
A. Lok
中科院分区：
文献类型：
--
作者：
A. Lok
全世界约有3.5亿B肝炎病毒（HBV）携带者，其中每年有50万至100万人死于肝病。慢性B型肝炎的治疗目标是预防肝硬化、肝衰竭和肝细胞癌。这一目标最好通过在不可逆的肝损伤发生之前根除HBV来实现。然而，由于存在HBV的肝外储库、HBV DNA整合到宿主基因组中以及存在使转录模板库（共价闭合）无效的细胞内转化途径，因此不可能实现HBV的根除。. .
Worldwide, there are approximately 350 million carriers of hepatitis B virus (HBV), of whom half a million to 1 million die from liver disease each year. The goal of treatment for chronic hepatitis B is to prevent cirrhosis, hepatic failure, and hepatocellular carcinoma. This goal is best achieved by eradicating HBV before irreversible liver damage occurs. However, the eradication of HBV is impossible to achieve because of the presence of extrahepatic reservoirs of HBV, the integration of HBV DNA into the host genome, and the presence of an intracellular conversion pathway that replenishes the pool of transcriptional templates (covalently closed . . .